Smart Port CT-Implantable Port Catalogue #: CT96STSD-VI, CT96STSA-VI - Product Usage: indicated f...
FDA Device Recall #Z-1466-2021 — Class II — February 22, 2021
Recall Summary
| Recall Number | Z-1466-2021 |
| Classification | Class II — Moderate risk |
| Date Initiated | February 22, 2021 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Angiodynamics Inc. (Navilyst Medical Inc.) |
| Location | Glens Falls, NY |
| Product Type | Devices |
| Quantity | 267 kits |
Product Description
Smart Port CT-Implantable Port Catalogue #: CT96STSD-VI, CT96STSA-VI - Product Usage: indicated for any patient requiring repeated access of the vascular system, for delivery of medications, nutritional supplementation, fluids, blood, blood products, and sampling of blood and power injection of contrast media for imaging.
Reason for Recall
AngioDynamics, Inc. is recalling a specific batch of AngioDynamics Implantable Infusion Port kits and Valved introducers that may have potential for compromised sterility of the device. Only the specific product/lot of the kit identified below is affected by this recall action. The Product Description, Product Number, Ref./Catalog Number and Batch/Lot number is provided below. No other products are affected by this recall.
Distribution Pattern
US Nationwide distribution in the states of AR, CA, CO, FL, HI, IL, IN, KS, MI, MO, NC, ND, NM, NY, OH, OR, PA, SC, TN, TX, VA, WA.
Lot / Code Information
UPN: H787CT96STSDVI1, Lot #: 5616651, 5647359, 5654135 UPN: H787CT96STSAVI1, Lot #: 5654129
Other Recalls from Angiodynamics Inc. (Navilyst Medical ...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-1467-2021 | Class II | AngioDynamics Safe Sheath Ultralite - Vascular ... | Feb 22, 2021 |
| Z-0411-2020 | Class II | Starburst Talon Semi-Flex Electrosurgical Devic... | Oct 2, 2019 |
| Z-0502-2020 | Class II | BIOFLO 8F SINGLE TITANIUM NON- FILLED; VALVED, ... | Sep 18, 2019 |
| Z-0504-2020 | Class II | BIOFLO 8F SINGLE PLASTIC FILLED; VALVED, UPN H9... | Sep 18, 2019 |
| Z-0501-2020 | Class II | BIOFLO 8F SINGLE PLASTIC FILLED; NON-VALVED, UP... | Sep 18, 2019 |
Frequently Asked Questions
Sterility recalls for medical devices vary in severity. If you have already had a procedure using a potentially non-sterile device, contact your healthcare provider immediately — you may need monitoring for signs of infection. Symptoms to watch for include fever, redness or swelling at the surgical site, unusual pain, or discharge. For devices that have not yet been used, they should be quarantined and returned to the manufacturer per the recall notice. Non-sterile implants can cause serious infections; early detection and treatment are critical.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.